treatment. Further, the therapy may prevent or reduce the adverse events and side-effects associated with conventional therapies, so that the therapy may be better tolerated than conventional therapies, such as risperidone or aripiprazole treatment.

[0007a] In one aspect, the present disclosure refers to a pharmaceutical composition comprising cannabidiol (CBD) and Δ^9-tetrahydrocannabinol (THC) in a ratio of CBD:THC from 4:1 to 1:45, one or more terpene or terpenoid compounds and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, wherein the terpene or terpenoid compounds include at least one of the following: eucalyptol, α-pinene, β-caryophyllene and β-myrcene.

[0007b] In another aspect, the present disclosure refers to a use of the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating autism.

[0007c] In another aspect, the present disclosure refers to a use of the pharmaceutical composition as disclosed herein, in the manufacture of a medicament for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof.

[0007d] In another aspect, the present disclosure refers to a pharmaceutical composition as disclosed herein for use in therapy~~kit comprising in separate parts: (a) CBD, and (b) THC, wherein the amount of CBD in part (a) and the amount of THC in part (b) are in a ratio of CBD:THC from 4:1 to 1:4, wherein at least one of (a) and (b) comprises one or more terpene or terpenoid compounds~~.

~~[0007e] In another aspect, the present disclosure refers to an agent for treating autism comprising CBD and THC in a ratio of CBD:THC from 4:1 to 1:4 and one or more terpene or terpenoid compounds.~~

~~[0007f] In another aspect, the present disclosure refers to a use of the agent as disclosed herein in the manufacture of a medicament for treating autism.~~

[0008] In one example, there is provided a pharmaceutical composition comprising CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 and optionally one or more pharmaceutically acceptable excipient(s).

[0009] In another example, there is provided a method for treating autism comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of the disclosure.

[0010] In a further example, there is provided a method for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of the disclosure.

4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5 or higher. In some embodiments, the ratio of THC:CBD may be between any of these values, for example, from 0.001 to 5, 0.1 to 5, 0.001 to 4, 0.1 to 4, 0.001 to 3, 0.2 to 3 or 0.4 to 2.6.

[0061] Typically, the *Cannabis* extract may also comprise other cannabinoids in addition to CBD and/or THC. These cannabinoids include Δ^9-Tetrahydrocannabinolic acid (THCA), Δ^9-Tetrahydrocannabivarin (THCV), (-)-Cannabidivarin (CBDV), Cannabinol ~~Cannabinodiol~~ (CBN) and Cannabigerol (CBG). Each of these cannabinoids may be present in an amount from about 0.001% to about 40% by weight of the *Cannabis* extract. Typically, the other cannabinoids are present in amounts lower than the primary cannabinoid or, if present, the secondary cannabinoid.

[0062] In some embodiments, certain cannabinoids may be absent, or present in non-detectable amounts (e.g. less than about 0.001% by weight of the analyte). In some embodiments, the *Cannabis* extract may exclude one or more of the following cannabinoids: Δ^9-Tetrahydrocannabinolic acid (THCA), Δ^9-Tetrahydrocannabivarin (THCV), Cannabidiolic acid (CBDA), Cannabinol ~~Cannabinodiol~~ (CBN), (-)-Cannabidivarin (CBDV), Cannabigerol (CBG) and Cannabichromene (CBC).

[0063] *Cannabis* extracts typically comprise non-cannabinoid compounds, which may include a terpene fraction. In some embodiments, the *Cannabis* extract comprises a terpene fraction in an amount of less than about 50% by weight, for example, less than about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2% or about 1% by weight of the extract. In some embodiments, the *Cannabis* extract may comprise terpene and terpenoid compounds in an amount of at least about 0.001% by weight of the extract, for example, at least about 0.005%, about 0.01%, about 0.05%, about 0.1%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 10%, about 15% or more of the total weight of the extract. In some embodiments, the *Cannabis* extract comprises about 0.001% to about 50% by weight of terpene and terpenoid compounds, for example, about 0.01% to about 50% by weight, about 0.01% to about 10% by weight, about 0.01% to about 6% by weight or about 0.01 to about 5% by weight of the pharmaceutical composition.

[0064] Typically, the terpene fraction in the plant material used to form the extract may have a different terpene/terpenoid profile than the terpene profile of the final extract, both in terms of the amounts of specific compounds in the terpene fraction and the weight of the

Claims

1. A pharmaceutical composition comprising cannabidiol (CBD) and Δ^9-tetrahydrocannabinol (THC) in a ratio of CBD:THC from 4:1 to ~~1:4~~1:5, one or more terpene or terpenoid compounds, and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, wherein the terpene or terpenoid compounds include at least one of the following: eucalyptol, α-pinene, β-caryophyllene and β-myrcene.

~~2. The composition of claim 1, wherein the pharmaceutical composition comprises a *Cannabis* extract comprising the CBD and the THC.~~

~~3. The composition of claim 2, wherein the *Cannabis* extract further comprises the one or more terpenes and/or terpenoids.~~

~~4. The composition of claim 2 or 3, wherein the *Cannabis* extract is macerated oil or a resin.~~

~~5. The composition of claim 2 or 3, wherein the *Cannabis* extract is formed by alcohol extraction of *Cannabis* plant material.~~

~~6. The composition of claim 5, wherein the alcohol is ethanol.~~

~~7. The composition of claim 4 or 5, wherein the *Cannabis* plant material used to form the extract is dried prior to extraction.~~

~~8. The composition of any one of claims 1-7, further comprising cannabigerol.~~

~~9~~2. The composition of ~~any one of~~ claim~~s~~ 1-~~8~~, wherein the composition is formulated for sublingual administration.

~~10~~3. The composition of ~~any one of~~ claim~~s~~ 1-~~9~~ or claim 2, wherein the pharmaceutical composition is in the form of a liquid.

~~11~~4. The composition of any one of claims 1-~~10~~3, comprising a carrier selected from olive oil, hemp oil, sesame oil, coconut oil, vegetable oil, canola oil, grape seed oil, almond oil, medium-chain triglyceride (MCT) oil, or a combination thereof.

~~12~~5. Use of the pharmaceutical composition according to any one of claims 1-~~11~~ 4 in the manufacture of a medicament for treating autism.

~~13~~6. Use of the pharmaceutical composition according to any one of claims 1-~~11~~4, in the manufacture of a medicament for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof.

~~14~~7. The use of claim ~~12~~ 5 or ~~13~~6, wherein treatment is maintained for at least about 12 weeks.

~~15~~8. The use of any one of claims ~~12-14~~5-7, wherein THC is to be administered in an amount of less than about 10 mg/day.

~~16~~9. The use of any one of claims ~~12-15~~5-8, wherein THC is to be administered in an amount from about 0.1-10 mg/day.

~~17~~10. The use of any one of claims ~~12-16~~5-9, wherein CBD is to be administered in an amount of less than about 20 mg/day.

~~18~~11. The use of any one of claims ~~12-17~~5-10, wherein CBD is to be administered in an amount from about 0.1-20 mg/day.

~~19~~12. The use of any one of claims ~~12-18~~5-11, wherein the pharmaceutical composition is to be administered twice daily.

~~20~~13. The use of any one of claims ~~12-19~~5-12, wherein the administration is sublingual administration.

14. A pharmaceutical composition as claimed in any one of claims 1-4 for use in therapy.

~~21. A kit comprising in separate parts: (a) CBD, and (b) THC, wherein the amount of CBD in part (a) and the amount of THC in part (b) are in a ratio of CBD:THC from 4:1 to 1:4, wherein at least one of (a) and (b) comprises one or more terpene or terpenoid compounds.~~

~~22. An agent for treating autism comprising CBD and THC in a ratio of CBD:THC from 4:1 to 1:4 and one or more terpene or terpenoid compounds.~~

~~23. An agent according to claim 22, further comprising cannabigerol.~~

~~24. Use of the agent of claim 22 or 23 in the manufacture of a medicament for treating autism.~~